News Daily News Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data Michael O'Riordan July 14, 2020
News Daily News Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE Michael O'Riordan July 08, 2020
News Conference News EuroPCR 2020 No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms Michael O'Riordan June 26, 2020
News Daily News Rural-Urban Gap Widens for Cardiometabolic Health Disparities Michael O'Riordan June 22, 2020
News Daily News Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19 Michael O'Riordan June 08, 2020
News Daily News Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions Michael O'Riordan May 29, 2020
News Features COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention Michael O'Riordan April 24, 2020
News Daily News ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients Caitlin E. Cox April 24, 2020
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Daily News ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice Yael L. Maxwell March 26, 2020
News Daily News Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives L.A. McKeown March 25, 2020
News Daily News Missed Opportunities: Many HF Patients Not Tested for CAD L.A. McKeown March 20, 2020
News Daily News Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease Michael O'Riordan March 13, 2020
News Daily News Type 2 MI Linked to More CV Deaths, Even in Younger Patients Shelley Wood March 04, 2020
News Daily News Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises Shelley Wood February 14, 2020
News Daily News Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds Michael O'Riordan February 06, 2020
News Daily News Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows L.A. McKeown January 17, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020